Follow the Pundits

Tag: ACAD

Editorial illustration of scientist-investors analyzing biotech data with glowing tickers MDGL, BGNE, and INCY, representing Baker Bros’ science-driven investing strategy.

Madrigal, BeiGene, and Biotech Alpha: Inside the “Gene-ius” Kingmakers of Baker Bros. 2025

Biotech Jedi at work. Baker Bros’ 2025 victory lap shows how Madrigal, BeiGene, and ruthless conviction turned science into serious alpha.

Read entire article

Tags: ACAD, Acadia Pharma, Alkermes, ALKS, Baker Bros, Baker Bros Advisors, BeiGene, best hedge funds, BGNE, Biotech Investing, Concentrated Portfolios, featured-hedge-funds, FUNanc1al Edge, FUNanc1al Humor, FUNanc1al Investing, FunFund Index, Healthcare Innovation, Hedge Funds, hub-hedge, INCY, Incyte, INSM, Insmed, Long-Term Investing, Madrigal Pharmaceuticals, Market Leaders, MDGL, Revolution Medicines, RVMD
Investor hiker climbing a brain-shaped Acadia National Park trail marked by biotech milestones, symbolizing ACADIA Pharmaceuticals’ growth potential.

ACADIA Pharmaceuticals: Biotech Powerhouse Baker Bros Still Believes. Should You Buy In?

Biotech heavyweight Baker Bros still owns over 25% of ACADIA Pharmaceuticals (ACAD), and the stock is heating up. With expanding revenue, a rich CNS pipeline, and smart money backing it, is this the comeback story investors have been waiting for?

Read entire article

Tags: ACAD, ACADIA Pharmaceuticals, Baker Bros, Biotech Investing, Biotech Stocks, Funanc1al, Funanc1al Contrarian Picks, Funanc1al for Investors, Funanc1al Investing, Funanc1alBiotech, Funanc1alEdge, Funanc1alFinance, Funanc1alFun, Funanc1alHumor, Funanc1alInsiders, Funanc1alInvesting, Funanc1alMentalHealth, Funanc1alPharma, Funanc1alStocks, Growth Investing, Hedge Funds Investing, High-Conviction Investing, insider holdings, Parkinson’s disease, pharma pipeline, Rett Syndrome